Small molecule inhibitors of receptor tyrosine kinases

Drugs of the Future

Volumn 24, Issue 5, 1999, Pages 515-537

  Boschelli, Diane H ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6 (METHYLAMINO)PYRIDO[3,4 D]PYRIMIDINE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4,5 BIS(4 FLUOROANILINO)PHTHALIMIDE; 4,5 DIANILINOPHTHALIMIDE; AG 18; AG 494; CGP 53326; CGP 59326; CL 387785; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBSTATIN; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; FLAVONE DERIVATIVE; GEFITINIB; GENISTEIN; LAVENDUSTIN A; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL]ACRYLAMIDE; NATURAL PRODUCT; PD 145709; PD 153717; PD 169540; PD 174265; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; QUERCETIN; QUINAZOLINE DERIVATIVE; STAUROSPORINE; TYRPHOSTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; ZD 1384;

CANCER; CLINICAL TRIAL; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; HUMAN; NONHUMAN; ORAL DRUG ADMINISTRATION; PSORIASIS; REVIEW; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION;

EID: 0033014592     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.05.858622     Document Type: Review

References (208)

1. Levitzki, A. Src as a target for anti-cancer drugs. Anti-Cancer Drug Des 1996, 11: 175-82.
2. Bolen, J.B., Brugge, J.S. Leukocyte protein tyrosine kinases: Potential targets for drug discovery. Annu Rev Immunol 1997, 15: 371-404.
3. Shawver, L.K., Lipson, K.E., Fong, A.T., McMahon, G., Plowman, G.D., Strawn, L.M. Receptor tyrosine kinases as targets for inhibition of angiogenesis. Drug Discov Today 1997, 2: 50-63.
4. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1: 27-31.
5. Mattsson, E., Clowes, A. W. Current concepts in restenosis following balloon angioplasty. Trends Cardiovasc Med 1995, 5: 200-4.
6. Shaw, L.A., Rudin, M., Cook, N.S. Pharmacological inhibition of restenosis: Learning from experience. Trends Pharmacol Sci 1995, 16: 401-4.
7. Raines, E.W., Ross, R. Multiple growth factors are associated with lesions of atherosclerosis: Specificity or redundancy? Bioessays 1996, 18: 271-82.
8. Bridges, A.J. The epidermal growth factor receptor family of tyrosine 'kinases and cancer: Can an atypical exemplar be a sound therapeutic target? Curr Med Chem 1996, 3: 167-94.
9. Traxler, P.M. Protein tyrosine kinase inhibitors in cancer treatment. Exp Opin Ther Patents 1997, 7: 571-88.
10. Kolibaba, K.S., Druker, B.J. Protein tyrosine kinases and cancer. Biochem Biophys Acta 1997, 1333: F217-48.
11. Bridges, A.J. Current progress towards the development of tyrosine kinase inhibitors as anticancer agents. Emerg Drugs 1998, 3: 279-92.
12. Hanks, S.K., Quinn, A.M., Hunter, T. The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains. Science 1988, 241: 42-52.
13. Burke, T.R. Jr. Protein-tyrosine kinase inhibitors. Drugs Fut 1992, 17: 119-31.
14. Levitzki, A., Gazit, A. Tyrosine kinase inhibition: An approach to drug development. Science 1995, 267: 1782-8.
15. Traxler, P., Lydon, N. Recent advances in protein tyrosine kinase inhibitors. Drugs Fut 1995, 20: 1261-74.
16. Spada, A.P., Myers, M.R. Small molecule inhibitors of tyrosine kinase activity. Exp Opin Ther Patents 1995, 5: 805-17.
17. Showalter, H.D.H., Kraker, A.J. Small molecule inhibitors of the platelet-derived growth factor receptor, the fibroblast growth factor receptor, and src family tyrosine kinases. Pharmacol Ther 1997, 76: 55-71.
18. Klohs, W.D., Fry, D.W., Kraker, A.J. Inhibitors of tyrosine kinase. Curr Opin Oncol 1997, 9: 562-8.
19. Lawrence, D.S., Niu, J. Protein kinase inhibitors: The tyrosine-specific protein kinases. Pharmacol Ther 1998, 77: 81-114.
20. Strawn, L.M., Shawver, L.K. Tyrosine kinases in disease: Overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials. Exp Opin Invest Drugs 1998, 7: 553-73.
21. Rusch, V., Mendelsohn, J., Dmitrovsky, E. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev 1996, 7: 133-41.
22. Davies, D.E., Chamberlin, S.G. Targeting the epidermal growth factor receptor for therapy of carcinomas. Biochem Pharmacol 1996, 51: 1101-10.
23. Modjtahedi, M., Dean, C. The receptor for EGF and its ligands: Expression, prognostic value and target for therapy in cancer. Int J Oncol 1994, 4: 277-96.
24. Barinaga, M. From benchtop to bedside. Science 1997, 278: 1036-9.
25. Genentech's Herceptin given FDA approval. DailyDrugNews.com (Daily Essentials), Sept 28, 1998.
26. Glossmann, H., Presek, P., Eigenbrodt, E. Quercetin inhibits tyrosine phosphorylation by the cyclic nucleotide-independent, transforming protein kinase, pp60src. Naunyn-Schmied Arch Pharmacol 1981, 317: 100-2.
27. Akiyama, T., Ishida, J., Nakagawa, S. et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987, 262: 5592-5.
28. Ruegg, U.T., Burgess, G.M. Staurosporine, K-252 and UNC-101: Potent but nonspecific inhibitors of protein kinases. Trends Pharmacol Sci 1989, 10: 218-20.
29. Onoda, T., Iinuma, H., Sasaki, Y. et al. Isolation of a novel tyrosine kinase inhibitor, lavendustin A, from Streptomyces griseolavendus. J Nat Prod 1989, 52: 1252-7.
30. Umezawa, H., Imoto, M., Sawa, T. et al. Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH435-hF3. J Antibiot 1986, 39: 170-3.
31. Yaish, P., Gazit, A., Gilon, C., Levitzki, A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 1988, 242: 933-5.
32. Osherov, N., Gazit, A., Gilon, C., Levitzki, A. Selective inhibition of the epidermal growth factor and HER2/Neu receptors by tyrphostins. J Biol Chem 1993, 268: 11134-42.
33. Gazit, A., Osherov, N., Posner, I., Bar-Sinai, A., Gilon, C., Levitzki, A. Tyrphostins. 3. Structure-activity relationship studies of alpha-substituted benzylidenemalononitrile 5-S-aryltyrphostins. J Med Chem 1993, 36: 3556-64.
34. Cushman, M., Zhu, H., Geahlen, R.L., Kraker, A.J. Synthesis and biochemical evaluation of a series of aminoflavones as potential inhibitors of protein-tyrosine kinases p56lck, EGFr, and p60v-src. J Med Chem 1994, 37: 3353-62.
35. Million, M-E., Mailliett, P., Chen, H. et al. Synthesis and biological evaluation of a new series of phenylhydroquinone derivatives as inhibitors of EGF-R associated PTK activity. Anti-Cancer Drug Des 1996, 11: 129-53.
36. Croisy-Delcey, M., Croisy, A., Mousset, S. et al. Genistein analogues: Effects on epidermal growth factor receptor tyrosine kinase and on stress-activated pathways. Biomed Pharmacother 1997, 51: 286-94.
37. Thompson, A.M., Rewcastle, G.W., Tercel, M. et al. Tyrosine kinase inhibitors. 1. Structure-activity relationships for inhibition of epidermal growth factor receptor tyrosine kinase activity by 2,3-dihydro-2-thioxo-1H-indole-3-alkanoic acids and 2,2′-dithiobis(1H-indole-3-alkanoic acids). J Med Chem 1993, 36: 2459-69.
38. Thompson, A.M., Fry, D.W., Kraker, A.J., Denny, W.A. Tyrosine kinase inhibitors. 2. Synthesis of 2,2′-dithiobis(1H-indole-3-alkanamides) and investigation of their inhibitory activity against epidermal growth factor receptor and pp60v-src protein tyrosine kinases. J Med Chem 1994, 37: 598-609.
39. Rewcastle, G.W., Palmer, B.D., Dobrusin, E.M., Fry, D.W., Kraker, A.J., Denny, W.A. Tyrosine kinase inhibitors. 3. Structure-activity relationships for inhibition of protein tyrosine kinases by nuclear-substituted derivatives of 2,2′-dithiobis(1-methyl-N-phenyl-1H-indole-3-carboxamide). J Med Chem 1994, 37: 2033-42.
40. Palmer, B.D., Rewcastle, G.W., Thompson, A.M. et al. Tyrosine kinase inhibitors. 4. Structure activity relationships among N- and 3-substituted 2,2′-dithiobis(1H-indoles) for in vitro inhibition of receptor and nonreceptor protein tyrosine kinases. J Med Chem 1995, 38: 58-67.
41. Fry, D.W., Nelson, J.M. Inhibition of basic fibroblast growth factor-mediated tyrosine phosphorylation and protein synthesis by PD 145709, a member of the 2-thioindole class of tyrosine kinase inhibitors. Anti-Cancer Drug Des 1995, 10: 607-22.
42. Showalter, H.D.H., Sercel, A.D., Leja, B.M. et al. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2′-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners. J Med Chem 1997, 40: 413-26.
43. Buchdunger, E., Trinks, U., Mett, H. et al. 4,5-Dianilinophthalimide: A protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proc Natl Acad Sci USA 1994, 91: 2334-8.
44. Trinks, U., Buchdunger, E., Furet, P. et al. Dianilinophthalimides: Potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. J Med Chem 1994, 37: 1015-27.
45. Buchdunger, E., Mett, H., Trinks, U. et al. 4,5-Bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity. Clin Cancer Res 1995, 1: 813-21.
46. Fry, D.W., Kraker, A.J., McMichael, A. et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994, 265: 1093-5.
47. Ward, W.H.J., Cook, P.N., Slater, A.M., Davies, D.H., Holdgate, G.A., Green, L.R. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem Pharmacol 1994, 48: 659-66.
48. Wakeling, A.E., Barker, A.J., Davies, D.H. et al. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res Treat 1996, 38: 67-73.
49. Bridges, A.J., Zhou, H., Cody, D.R. et al. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem 1996, 39: 267-76.
50. Denny, W.A., Rewcastle, G.W., Bridges, A.J., Fry, D.W., Kraker, A.J. Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro. Clin Exp Pharmacol Physiol 1996, 23: 424-7.
51. Rewcastle, G.W., Denny, W.A., Bridges, A.J. et al. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J Med Chem 1995, 38: 3482-7.
52. Bridges, A.J., Cody, D.R., Zhou, H., McMichael, A., Fry, D.W. Enantioselective inhibition of the epidermal growth factor receptor tyrosine kinase by 4-(α-phenethylamino)quinazolines. Bioorg Med Chem 1995, 3: 1651-6.
53. Thompson, A.M., Bridges, A.J., Fry, D.W., Kraker, A. J., Denny, W.A. Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]-pyrido[4,3-d]pyrimidines: A new class of inhibitors of tyrosine kinase activity of the epidermal growth factor receptor. J Med Chem 1995, 38: 3780-8.
54. Rewcastle, G.W., Palmer, B.D., Thompson, A.M. et al. Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]pyrimides are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor. J Med Chem 1996, 39: 1823-35.
55. Fry, D.W., Nelson, J.M., Slintak, V. et al. Biochemical and antiproliferative properties of 4[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor. Biochem Pharmacol 1997, 54: 877-87.
56. Kunkel, M.W., Hook, K.E., Howard, C.T. et al. Inhibition of the epidermal growth factor receptor tyrosine kinase by PD 153035 in human A431 tumors in athymic nude mice. Invest New Drugs 1996, 13: 295-302.
57. Tomic-Canic, M., Komine, M., Freedberg, I.M., Blumenberg, M. Epidermal signal transduction and transcription factor activation in activated keratinocytes. J Dermatol Sci 1998, 17: 167-81.
58. Thompson, A.M., Murray, D.K., Elliott, W.L. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J Med Chem 1997, 40: 3915-25.
59. Rewcastle, G.W., Murray, D.K., Elliot, W.L. et al. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors of the EGF family of growth factors. J Med Chem 1998, 41: 742-51.
60. Rewcastle, G.W., Bridges, A.J., Fry, D.W., Rubin, J.R., Denny, W.A. Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenyl-amino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor. J Med Chem 1997, 40: 1820-6.
61. Rewcastle, G.W., Palmer, B.D., Bridges, A.J. et al. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J Med Chem 1996, 39: 918-28.
62. Palmer, B.D., Trumpp-Kallmeyer, S., Fry, D.W., Nelson, J.M., Showalter, H.D.H., Denny, W.A. Tyrosine kinase inhibitors. 11. Soluble analogs of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: Synthesis, biological evaluation, and modeling of the mode of binding. J Med Chem 1997, 40: 1519-29.
63. Singh, J., Dobrusin, E.M., Fry, D.W., Haske, T., Whitty, A., McNamara, D.J. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases. J Med Chem 1997, 40: 1130-5.
64. Zhou, H., Bridges, A.J., Denny, W.A. et al. An examination of the Michael acceptor sidechain for irreversible EGFr inhibitors related to PD 158780. 89th Annu Meet Am Assoc Cancer Res (Mar 28-Apr 1, New Orleans) 1998, Abst 2154.
65. Fry, D.W., Bridges, A.J., Denny, W.A., et al. Specific irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci USA 1998, 95: 12022-7.
66. Hook, K.E., Vincent, P.W., Elliott, W.L. et al. Comparative antitumor activity of the irreversible EGF receptor tyrosine kinase inhibitor PD 168393 and its reversible congener PD 174265 in nude mice. 89th Annu Meet Am Assoc Cancer Res (Mar 28-Apr 1, New Orleans) 1998, Abst 2157.
67. Patmore, S.J., Roberts, B.J., Stoner, C.L., Vincent, P.W., Dykes, D.J. In vivo evaluation of the irreversible EGF receptor tyrosine kinase inhibitor PD 168393. 89th Annu Meet Am Assoc Cancer Res (Mar 28-Apr 1, New Orleans) 1998, Abst 3805.
68. Denny, W.A., Smaill, J.B., Fry, D.W. et al. Structure-activity relationships for 4-anilinoquinazolines and related pyridopyrimidine acrylamides as specific, irreversible inhibitors of the ATP site of the epidermal growth factor receptor. 89th Annu Meet Am Assoc Cancer Res (Mar 28-Apr 1, New Orleans) 1998, Abst 3804.
69. Denny, W.A. Quinazoline and pyridopyrimidine acrylamides: A new class of potent and selective irreversible inhibitors of the tyrosine kinase activity of the epidermal growth factor. 215th Am Chem Soc Natl Meet (Mar 19-Apr 2, Dallas) 1998, MEDI-118.
70. Denny, W.A. ATP site-directed kinase inhibitors. Drugs 1998, 1: 10-2.
71. Bridges, A.J., Zhou, H., Fry, D.W. et al. Changed mechanisms and potency of inhibition of the EGFr tyrosine kinase by the enantiomers of 6-acrylamido-4-(α-phenethylamino) quinazoline. 89th Ann J Meet Am Assoc Cancer Res (Mar 28-Apr 1, New Orleans) 1998, Abst 2159.
72. Zhou, H., Bridges, A.J., Trumpp-Kallmeyer, S., Fry, D., Nelson, J.M. Modeling assisted irreversible EGFr inhibitor design: Regiospecificity of 6-acrylamido-4-[(3-bromo)anilino]-benzothienopyrimidine. 216th Am Chem Soc Natl Meet (Aug 23-27, Boston) 1998, MEDI-268.
73. Wissner, A., Johnson, B.D., Floyd, M.B. Jr., Kitchen, D.B. 4-Aminoquinazoline EGFR inhibitors. US 5760041, 1998.
74. Discafani, C.M., Carroll, M., Floyd, M.B. Jr. et al. CL-387,785: An irreversible inhibitor of epidermal growth factor receptor tyrosine kinase with in vivo activity. Biochem Pharmacol 1999, 57: 917-25.
75. Gibson, K.H., Grundy, W., Godfrey, A.A. et al. Epidermal growth factor receptor tyrosine kinase: Structure-activity relationships and antitumor activity of novel quinazolines. Bioorg Med Chem Lett 1997, 7: 2723-8.
76. Woodburn, J.R., Barker, A.J., Gibson, K.H. et al. ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development. 88th Annu Meet Am Assoc Cancer Res (Apr 12-16, San Diego) 1997, Abst 695.
77. ZD1839, an EGFR-TK inhibitor worthy of further testing. DailyDrugNews.com (Daily Essentials) Jun 23, 1998.
78. Moyer, J.D., Barbacci, E.G., Iwata, K.K. et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997, 57: 4838-48.
79. Pollack, V.A., Savage, D.M., Baker, D.A. et al. Therapy of human carcinomas in athymic mice by inhibition of EGF receptor-mediated signal transduction with CP-358774: Dynamics of receptor inhibition and anti-tumor effects. 88th Annu Meet Am Assoc Cancer Res (Apr 12-16, San Diego) 1997, Abst 1173.
80. Iwata, K., Miller, P.E., Barbacci, E.G. et al. CP-358,774: A selective EGFR kinase inhibitor with potent antiproliferative activity against HN5 head and neck tumor cells. 88th Annu Meet Am Assoc Cancer Res (Apr 12-16, San Diego) 1997, Abst 4248.
81. Traxler, P.M., Furet, P., Mett, H., Buchdunger, E., Meyer, T., Lydon, N. 4-(Phenylamino)-pyrrolopyrimidines: Potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. J Med Chem 1996, 39: 2285-92.
82. Traxler, P., Furet, P., Mett, H., Buchdunger, E., Meyer, T., Lydon, N. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R. J Pharm Belg 1997, 52: 88-96.
83. Lydon, N.B., Mett, H., Mueller, M. et al. A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo. Int J Cancer 1998, 76: 154-63.
84. Traxler, P., Bold, G., Frei, J. et al. Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: 4-(Phenylamino)pyrazolo[3,4-d]pyrimidines. J Med Chem 1997, 40: 3601-16.
85. Trumpp-Kallmeyer, S., Rubin, J.R., Humblet, C., Hamby, J.M., Showalter, H.D.H. Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors. J Med Chem 1998, 41: 1752-63.
86. O'Reilly, M.S., Holmgren, L., Shing, Y. et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79: 315-28.
87. O'Reilly, M.S., Holmgren, L., Chen, C., Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996, 2: 689-92.
88. O'Reilly, M.S., Boehm, T., Shing, Y. et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88: 277-85.
89. Boehm, T., Folkman, J., Browder, T., O'Reilly, M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997, 390: 404-7.
90. Folkman, J., Ingher, D. Inhibition of angiogenesis. Cancer Biol 1992, 3: 89-96.
91. Mousa, S.A. Mechanisms of angiogenesis in vascular disorders: Potential therapeutic targets. Drugs Fut 1998, 23: 51-60.
92. Nicosia, R.F. What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? Am J Pathology 1998, 153: 11-6.
93. Slavin, J. Fibroblast growth factors: At the heart of angiogenesis. Cell Biol Int 1995, 19: 431-44.
94. Friesel, R.E., Maciag, T. Molecular mechanisms of angiogenesis: Fibroblast growth factor signal transduction. FASEB J 1995, 9: 919-25.
95. Libby, P., Schwartz, D., Brogi, E., Tanaka, H., Clinton, S.K. A cascade model for restenosis: A special case of atherosclerosis progression. Circulation 1992, 86: 47-52.
96. Yamaguchi, T.P., Rossant, J. Fibroblast growth factors in mammalian development. Curr Opin Genetics Dev 1995, 5: 485-91.
97. Ohbayashi, N., Hoshikawa, M., Kimura, S., Yamasaki, M., Fukui, S., Itoh, N. Structure and expression of the mRNA encoding a novel fibroblast growth factor, FGF-18. J Biol Chem 1998, 273: 18161-4.
98. Ornitz, D.M., Xu, J., Colvin, J.S. et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996, 271: 15292-7.
99. Mohammadi, M., McMahon, G., Sun, L. et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997, 276: 955-60.
100. Sun, L., Tran, N., Tang, F. et al. Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J Med Chem 1988, 41: 2588-603.
101. Hamby, J.M., Connolly, C.J.C., Schroeder, M.C. et al. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J Med Chem 1997, 40: 2296-303.
102. Connolly, C.J.C., Hamby, J.M., Schroeder, M.C. et al. Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Bioorg Med Chem Lett 1997, 7: 2415-20.
103. Panek, R.L., Lu, G.H., Dahring, T.K. et al. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase. J Pharmacol Exp Ther 1998, 286: 569-77.
104. Bately, B.L., Doherty, A.M., Hamby, J.M. et al. Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitor. Life Sci 1998, 62: 143-50.
105. Barvian, M.R., Panek, R.L., Lu, G.H. et al. 1-Oxo-3-aryl-1H-indene-2-carboxylic acid derivatives as selective inhibitors of fibroblast growth factor receptor-1 tyrosine kinase. Bioorg Med Chem Lett 1997, 7: 2903-8.
106. Senger, D.R., Galli, S.J., Dvorak, A.M., Peruzzi, C.A., Harvey, V.S., Dvorak, H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219: 983-5.
107. Ferrara, N., Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocrine Rev 1997, 18: 4-25.
108. Augustin, H.G. Antiangiogenic tumor therapy: Will it work? Trends Pharmacol Sci 1998, 19: 216-22.
109. Korpelainen, E.I., Alitalo, K. Signaling angiogenesis and lymphangiogenesis. Curr Opin Cell Biol 1998, 10: 159-64.
110. Kim, K.J., Li, B., Winer, J. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993, 362: 841-4.
111. Borgstrom, P., Bourdon, M.A., Hillan, K.J., Sriramarao, P., Ferrara, N. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 1998, 35: 1-10.
112. Kanal, T., Konno, H., Tanaka, T. et al. Anti-tumor and anti-metastatic effects of human vascular endothelial growth factor neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int J Cancer 1998, 77: 933-6.
113. Asano, M., Yukita, A., Matsumoto, T., Hanatani, M., Suzuki, H. An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo. Hybridoma 1998, 17: 185-90.
114. Presta, L.G., Chen, H., O'Connor, S.J. et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57: 4593-9.
115. Benjamin, L.E., Keshet, E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 1997, 94: 8761-6.
116. Claffey, K.P., Brown, L.F., Del Aguila, L.F. et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 1996, 56: 172-81.
117. Cheng, S-Y., Huang, H-J.S., Nagane, M. et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 1996, 93: 8502-7.
118. Goldman, C.K., Kendall, R.L., Cabrera, G. et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 1998, 95: 8795-800.
119. Millauer, B., Shawver, L.K., Plate, K.H., Risau, W., Ullrich, A. Glioblastoma growth inhibited in vivo by a dominant-negative flk-1 mutant. Nature 1994, 367: 576-9.
120. Millauer, B., Longhi, M.P., Plate, K.H. et al. Dominant-negative inhibition of flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 1996, 56: 1615-20.
121. Strawn, L.M., McMahon, G., App, H. et al. Flk-1 as a target for tumor growth inhibition. Cancer Res 1996, 56: 3540-5.
122. Gazit, A., App, H., McMahon, G., Chen, J., Levitzki, A., Bohmer, F.D. Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: Structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins. J Med Chem 1996, 39: 2170-7.
123. Fong, T.A.T., Shawver, L.K., App, H. et.al. SU5416; A potent and selective flk-1/KDR kinase inhibitor that blocks flk-1 phosphorylation, endothelial cell mitogenesis, and tumor growth. 89th Annu Meet Am Assoc Cancer Res (Mar 28-Apr 1, New Orleans) 1998, Abst 3811.
124. Sun, L., Tran, N., Tang, F. et al. Synthesis and biological evaluation of novel 3-(substituted pyrrol-2-yl)indolin-2-ones as potent and selective inhibitors of the flk-1/KDR receptor tyrosine kinase. 215th Am Chem Soc Natl Meet (Mar 29-Apr 2, Dallas) 1998, MEDI-022.
125. Promising interim results announced for SU-5416 phase I trial. DailyDrugNews.com (Daily Essentials) Nov 10, 1998.
126. Sato, T.N., Tozawa, Y., Deutsch, U. et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995, 376: 70-4.
127. Dumont, D.J., Gradwohl, G.J., Fong, G.H., Auerbach, R., Breitman, M.L. The endothelial-specific receptor tyrosine kinase, Tek, is a member of a new subfamily of receptors. Oncogene 1993, 8: 1293-301.
128. Molloy, C.J. Novel signal transaction targets in cardiovascular disease: Role of platelet-derived growth factor in vascular smooth muscle cell proliferation. Drug Dev Res 1993, 29: 148-57.
129. Hughes, A.D., Clunn, G.F., Refson, J., Demoliou-Mason, C. Platelet-derived growth factor (PDGF): Actions and mechanisms in vascular smooth muscle. Gen Pharmacol 1996, 27: 1079-89.
130. Stanley, E.R., Berg, K.L., Einstein, D.B. et al. Biology and action of colony-stimulating factor-1. Mol Reprod Dev 1997, 46: 4-10.
131. Kanakura, Y., Ikeda, H., Tsujimura, T., Kitayama, H. The c-kit receptor tyrosine kinase: Its role in hematological malignancies. Cancer J 1996, 9: 79-82.
132. Jackson, C.L., Raines, E.W., Ross, R., Reidy, M.A. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arterioscler Thromb 1993, 13: 1218-26.
133. Sirois, M.G., Simons, M., Edelman, E.R. Antisense oligonucleotide inhibition of PDGFR-β receptor subunit expression directs suppression of intimal thickening. Circulation 1997, 95: 669-76.
134. Waterfield, M.D., Scrace, G.T., Whittle, N. et al. Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus. Nature 1983, 304: 35-9.
135. Doolittle, R.F., Hunkapiller, M.W., Hood, L.E. et al. Simian sarcoma virus one gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor. Science 1983, 221: 275-7.
136. Nister, M., Libermann, T.A., Betsholtz, C. et al. Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. Cancer Res 1988, 48: 3910-8.
137. Nister, M., Claesson-Welsh, L., Eriksson, A., Heldin, C-H., Westermark, B. Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. J Biol Chem 1991, 266: 16755-63.
138. Hermanson, M., Funa, K., Hartman, M. et al. Platelet-derived growth factor and its receptors in human glioma tissue: Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992, 52: 3213-9.
139. Fleming, T.P., Matsui, T., Heidaran, M.A., Molloy, C.J., Artrip, J., Aaronson, S.A. Demonstration of an activated platelet-derived growth factor autocrine pathway and its role in human tumor cell proliferation in vitro. Oncogene 1992, 7: 1355-9.
140. Strawn, L.M., Mann, E., Elliger, S.S. et al. Inhibition of glioma cell growth by a truncated platelet-derived growth factor-beta receptor. J Biol Chem 1994, 269: 21215-22.
141. Maguire, M.P., Sheets, K.R., McVety, K., Spada, A.P., Zilberstein, A. A new series of PDGF receptor tyrosine kinase inhibitors: 3-Substituted quinoline derivatives. J Med Chem 1994, 37: 2129-37.
142. Dolle, R.E., Dunn, J.A., Bobko, M. et al. 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular β-type platelet-derived growth factor receptor tyrosine kinase. J Med Chem 1994, 37: 2627-9.
143. Kovalenko, M., Gazit, A., Bohmer, A. et al. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res 1994, 54: 6106-14.
144. Kovalenko, M., Ronnstrand, L., Heldin, C-H. et al. Phosphorylation site-specific inhibition of platelet-derived growth factor β-receptor autophosphorylation by the receptor blocking tyrphostin AG1296. Biochemistry 1997, 36: 6260-9.
145. Banal, S., Wolf, Y., Colomb, G. et al. PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. Circulation 1998, 97: 1960-9.
146. Kubo, K., Shimizu, T., Ohyama, S. et. al. A novel series of 4-phenoxyquinolines: Potent and highly selective inhibitors of PDGF receptor autophosphorylation. Bioorg Med Chem Lett 1997, 7: 2935-40.
147. Yagi, M., Kato, S., Kobayashi, Y. et al. Selective inhibition of platelet-derived growth factor (PDGF) receptor autophosphorylation and PDGF-mediated cellular events by a quinoline derivative. Exp Cell Res 1997, 234: 285-92.
148. Buchdunger, E., Zimmerman, J., Mett, H. et al. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci USA 1995, 92: 2558-62.
149. Zimmermann, J., Caravatti, G., Mett, H. et al. Phenylaminopyrimidine (PAP) derivatives: A new class of potent and selective inhibitors of protein kinase C (PKC). Arch Pharm 1996, 329: 371-6.
150. Major, T.C., Keiser, J.A. Inhibition of cell growth: Effects of the tyrosine kinase inhibitor CGP 53716. J Pharmacol Exp Ther 1997, 283: 402-10.
151. Myllamiemi, M., Calderon, L., Lemstrom, K., Buchdunger, E., Hayry, P. Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation. FASEB J 1997, 11: 1119-26.
152. Zimmerman, J., Buchdunger, E., Mett, H., Meyer, T., Lydon, N.B., Traxler, P. Phenylamino-pyrimidine (PAP) derivatives: A new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors. Bioorg Med Chem Lett 1996, 6: 1221-6.
153. Buchdunger, E., Zimmermann, J., Mett, H. et al. Inhibition of the abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996, 56: 100-4.
154. Zimmerman, J., Buchdunger, E., Mett, H., Meyer, T., Lydon, N.B. Potent and selective inhibitors of the abl-kinase: Phenylaminopyrimidine (PAP) derivatives. Bioorg Med Chem Lett 1997, 7: 187-92.
155. Druker, B.J., Tamura, S., Buchdunger, E. et al. Effects of a selective inhibitor of the abl tyrosine kinase on the growth of bcr-abl positive cells. Nat Med 1996, 2: 561-6.
156. Carroll, M., Ohno-Jones, S., Tamura, S. et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing bcr-abl, tel-abl, and tel-PDGFR fusion proteins. Blood 1997, 90: 4947-52.
157. Deininger, M.W.N., Goldman, J.M., Lydon, N., Melo, J.V. The tyrosine kinase inhibitor CGP 57148B selectively inhibits the growth of bcr-abl-positive cells. Blood 1997, 90: 3691-8.
158. Beran, M., Cao, X., Estrov, Z. et al. Selective inhibition of cell proliferation and bcr-abl phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 bcr-abl protein by a tyrosine kinase inhibitor (CGP-57148), Clin Cancer Res 1998, 4: 1661-72.
159. Zimmermann, J., Buchdunger, E., Fabbro, D. et al. A new class of highly selective protein kinase-inhibitors: Phenylaminopyrimidines. 215th Am Chem Soc Natl Meet (Mar 29-Apr 2, Dallas) 1998, MEDI-103.
160. Ruetz, S., Woods Cook, K., Solf, R., Meyer, T., Zimmermann, J., Fabbro, D. Effect of CGP 60474 on cyclin dependent kinases (CDKs), cell cycle progression and onset of apoptosis in normal and transformed cells. 89th Annu Meet Am Assoc Cancer Res (Mar 28-Apr 1, New Orleans) 1998, Abst 3796.
161. Meyer, T., Zimmermann, J., Geiger, T., Mett, H., Buchdunger, E., Mueller, M. CGP 60474, a protein kinase inhibitor with potent antitumor activity in vivo at well tolerated doses. 89th Annu Meet Am Assoc Cancer Res (Mar 28-Apr 1, New Orleans) 1998, Abst 3794.
162. Sawutz, D.G., Bode, D.C., Briggs, G.M. et al. In vitro characterization of a novel series of platelet-derived growth factor receptor tyrosine kinase inhibitors. Biochem Pharmacol 1996, 51: 1631-8.
163. Spacey, G.D., Ulings, I.J., Slater, M., Hirst, S., Bonser, R.W. Indolocarbazoles. Potent and selective inhibitors of platelet-derived growth factor receptor autophosphorylation. Biochem Pharmacol 1998, 55: 261-71.
164. Klutchko, S.R., Hamby, J.M., Boschelli, D.H. et al. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. J Med Chem 1998, 41: 3276-92.
165. Panek, R.L., Lu, G.H., Klutchko, S.R. et al. In vitro pharmacological characterization of PD 166265, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J Pharmacol Exp Ther 1998, 283: 1433-44.
166. Boschelli, D.H., Wu, Z., Klutchko, S.R. et al. The synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines. Identification of potent, selective platelet derived growth factor receptor tyrosine kinase inhibitors. J Med Chem 1998, 41: 4365-77.
167. Showalter, H.D.H., Klutchko, S., Boschelli, D. et al. The development of substituted 2-anilinopyrido[2,3-d]pyrimidines as novel, potent inhibitors of the c-src tyrosine kinase. 88th Annu Meet Am Assoc Cancer Res (Apr 12-16, San Diego) 1997, Abst 3146.
168. Kraker, A.J., Moore, C.W., Amar, A.M. et al. Cytotoxicity and phosphotyrosine effects of c-src kinase inhibition by substituted pyridopyrimidine tyrosine kinase inhibitors of human colon carcinoma cell lines. 88th Annu Meet Am Assoc Cancer Res (Apr 12-16, San Diego) 1997, Abst 4247.
169. Boschelli, D.H., Dobrusin, E.M., Doherty, A.M. et al. Pyrido[2,3-d]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation. WO 9833798, 1998.
170. Shawver, L.K., Schwartz, D.P., Taylorson, L.T. et al. SU101, a potent inhibitor of PDGF-mediated signaling, inhibits growth of a wide variety of tumor types in vivo. 87th Annu Meet Amn Assoc Cancer Res (Apr 20-24, Washington, DC) 1996, Abst 2721.
171. Mason, W., Malkin, M., Lieberman, F., Cropp, G., Hannah, A. Pharmacokinetics of SU 101, a novel signal transduction inhibitor, in patients with recurrent malignant glioma. 87th Annu Meet Am Assoc Cancer Research (Apr 20-24, Washington, DC) 1996, Abst 1145.
172. Bartlett, R.R., Brendel, S., Zielinski, T., Schorlemmer, H.U. Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis. Transplant Proc 1996, 28: 3074-8.
173. Scott, D.L., Strand, V. Leflunomide: A new immunosuppressive drug. In: Novel Therapeutic Agents in the Treatment of Autoimmune Disease. Strand, V., Scott, D.U., Simon, L.S. (Eds.). Dekker: New York 1997, 287-293.
174. Leflunomide market introduction announced. DailyDrugNews.com (Daily Essentials) Oct 7, 1998.
175. Mattar, T., Kochhar, K., Bartlett, R., Bremer, E.G., Finnegan, A. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett 1993, 334: 161-4.
176. Xu, X., Williams, J.W., Bremer, E.G., Finnegan, A., Chong, A.S-F. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosupressive agent, leflunomide. J Biol Chem 1995, 270: 12398-403.
177. Xu, X., Williams, J.W., Gong, H., Finnegan, A., Chong, A.S.F. Two activities of the immunosuppresive metabolite of leflunomide, A771726. Biochem Pharmacol 1996, 52: 527-34.
178. Shawver, L.K., Schwartz, D.P., Mann, E. et al. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)phenyl]-5-methylisoxazole-4-carboxamide. Clin Cancer Res 1997, 3: 1167-77.
179. Lipson, K.E., Wang, X., Chen, H. et al. SU 101, and not its major metabolite, inhibits PDGF-dependent receptor tyrosine phosphorylation, cell cycle progression, and human tumor cell growth. 89th Annu Meet Am Assoc Cancer Res (Mar 28-Apr 1, New Orleans) 1998, Abst 3797.
180. Shawver, L.K., Sutton, B., West, K.A., Cropp, G.F., Strawn, L.M., Powell, T.J. The anti-tumor efficacy of SU101 in human tumor models is exerted by the parent compound and not the metabolite. 89th Annu Meet Am Assoc Cancer Res (Mar 28-Apr 1, New Orleans) 1998, Abst 2185.
181. Sugen initiates two new trials with lead compound. DailyDrugNews.com (Daily Essentials) Sept 22, 1998.
182. Strawn, M., Shawver, L.K. SU101 combination treatment increases the efficacy of BCNU in a human glioblastoma model. 89th Annu Meet Am Assoc Cancer Res (Mar 28-Apr 1, New Orleans) 1998, Abst 2120.
183. Roussel, M.F. Signal transduction by the macrophage-colony-stimulating factor receptor (CSF-1R). J Cell Sci Suppl 1994, 18: 105-8.
184. Kacinski, B.M. CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract. Mol Reprod Dev 1997, 46: 71-4.
185. Fixe, P., Praloran, V. M-CSF: Haematopoietic growth factor or inflammatory cytokine? Cytokine 1998, 10: 32-7.
186. Myers, M.R., Setzer, N.N., Spada, A.P. et al. The synthesis and SAR of new 4-(N-alkyl-N-phenyl)amino-6,7-dimethoxyquinazolines and 4-(N-alkyl-N-phenyl)amino-pyrazolo[3,4-d]pyrimidines, inhibitors of CSF-1R tyrosine kinase activity. Bioorg Med Chem Lett 1997, 7: 421-4.
187. Myers, M.R., Setzer, N.N., Spada, A.P. et al. The preparation and SAP of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: Inhibitors of p56lck and EGF-R tyrosine kinase activity. Bioorg Med Chem Lett 1997, 7: 417-20.
188. Schrank, B., Sendtner, M. Brain-derived neurotrophic factor. Drugs Fut 1997, 22: 969-73.
189. Kaplan, D.R., Stephans, R.M. Neurotrophin signal transduction by the trk receptor. J Neurobiol 1994, 25: 1404-17.
190. Miknyoczki, S.J., Klein-Szanto, A.J.P., Ruggeri, B.A. Neurotrophin-trk receptor interactions in neoplasia: A possible role in interstitial and perineural invasion in ductal pancreatic cancer. Crit Rev Oncogenesis 1996, 7: 89-100.
191. Dalal, R., Djakiew, D. Molecular characterization of neurotrophin expression and the corresponding tropomyosin receptor kineses (trks) in epithelial and stromal cells of the human prostate. Mol Cell Endocrinol 1997, 134: 15-22.
192. Pflug, B.R., Dionne, C., Kaplan, D.R., Lynch, J., Djakiew, D. Expression of a trk high affinity nerve growth factor receptor in the human prostate. Endocrinology 1995, 136: 262-8.
193. Tapley, P., Lamballe, F., Barbacid, M. K252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotropin receptors. Oncogene 1992, 7: 371-81.
194. Kaneko, M., Saito, Y., Saito, H. et al. Neurotrophic 3,9-bis[(alkylthio)methyl]- and -bis(alkoxymethyl)-K-252a derivatives. J Med Chem 1997, 40: 1863-9.
195. Camoratto, A.M., Jani, J.P., Angeles, T.S. et al. CEP-751 inhibits trk receptor tyrosine kinase activity in vitro and exhibits anti-tumor activity. Int J Cancer 1997, 72: 673-9.
196. Hudkins, R.L., Murakata, C., Kaneko, M., Angeles, T.S., Dionne, C.A., Neff, N.T. Selective trkA tyrosine kinase inhibitors. 215th Am Chem Soc Natl Meet (Mar 29-Apr 2, Dallas) 1998, MEDI-117.
197. George, D.J., Dionne, C.A., Jani, J., Lamb, J., Issacs, J. T. Combined effects of the trk tyrosine kinase inhibitor, CEP-751 (KT-6587), and castration on the growth of Dunning H rat prostate cancers in vivo. 89th Annu Meet Am Assoc Cancer Res (Mar 28-Apr 1, New Orleans) 1998, Abst 4387.
198. Dionne, C.A., Camoratto, A.M., Jani, J.P. et al. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin Cancer Res 1998, 4: 1887-98.
199. Hudkins, R.L., Iqbal, M., Park, C-H. et al. Prodrug esters of the indolocarbazole, CEP-751 (KT-6587). Bioorg Med Chem Lett 1998, 8: 1873-6.
200. Ouwens, D.M., Maassen, J.A. Signaling by insulin receptors and related protein tyrosine kinases. Biomed Rev 1996, 5: 5-30.
201. Srinivas, P.R., Grunberger, G. Inhibitors of the insulin receptor tyrosine kinase. Pharmacol Ther 1994, 64: 23-35.
202. Blakesley, V.A., Stannard, B.S., Kalebic, T., Helman, L.J., Le Roith, D. Role of the IGF-1 receptor in mutagenesis and tumor promotion. J Endocrinol 1997, 152: 339-44.
203. Resnik, J.L., Reichart, D.B., Huey, K., Webster, N.J.G., Seely, B.L. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 1998, 58: 1159-64.
204. Werner, H., Le Roith, D. The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. Crit Rev Oncogenesis 1997, 8: 71-92.
205. Tamagnone, L., Comoglio, P.M. Control of invasive growth by hepatocyte growth factor (HGF) and related scatter factors. Cytokine Growth Factor Rev 1997, 8: 129-42.
206. Jeffers, M., Rong, S., Vande Woude, G.F. Hepatocyte growth factor/scatter factor-met signaling in tumorigenicity and invasion/metastasis. J Mol Med 1996, 74: 505-13.
207. Zhou, R. The EPH family receptors and ligands. Pharmacol Ther 1998, 77: 151-81.
208. Stein, E., Schoecklmann, H., Daniel, T.O. EPH family receptors and ligands in vascular cell targeting and assembly. Trends Cardiovasc Med 1997, 7: 329-34.